VAV3 mediates resistance to breast cancer endocrine therapy

INTRODUCTION: Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially responsive to these therapies acquire resistance through mechanisms that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilar, Helena, Urruticoechea, Ander, Halonen, Pasi, Kiyotani, Kazuma, Mushiroda, Taisei, Barril, Xavier, Serra-Musach, Jordi, Islam, Abul, Caizzi, Livia, Di Croce, Luciano, Nevedomskaya, Ekaterina, Zwart, Wilbert, Bostner, Josefine, Karlsson, Elin, Pérez Tenorio, Gizeh, Fornander, Tommy, Sgroi, Dennis C, Garcia-Mata, Rafael, Jansen, Maurice PHM, García, Nadia, Bonifaci, Núria, Climent, Fina, Soler, María Teresa, Rodríguez-Vida, Alejo, Gil, Miguel, Brunet, Joan, Martrat, Griselda, Gómez-Baldó, Laia, Extremera, Ana I, Figueras, Agnes, Balart, Josep, Clarke, Robert, Burnstein, Kerry L, Carlson, Kathryn E, Katzenellenbogen, John A, Vizoso, Miguel, Esteller, Manel, Villanueva, Alberto, Rodríguez-Peña, Ana B, Bustelo, Xosé R, Nakamura, Yusuke, Zembutsu, Hitoshi, Stål, Olle, Beijersbergen, Roderick L, Pujana, Miguel Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076632/
https://www.ncbi.nlm.nih.gov/pubmed/24886537
http://dx.doi.org/10.1186/bcr3664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076632/
https://www.ncbi.nlm.nih.gov/pubmed/24886537
http://dx.doi.org/10.1186/bcr3664

Ejemplares similares